Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Negative Cashflow GRAL offers strong liquidity and low leverage, but persistent losses, heavy cash burn, intangible-asset reliance, and elevated valuation make the risk/reward profile unattractive.
Price Behavior
Key Price Behavior Insights: ⢠Strong upward momentum ⢠Key resistance test ⢠Elevated volatility Support Level: $79.30â$80.00; deeper support $76.60â$78.00 Resistance Level: $82.50â$82.60 GRAL remains bullish over the last month above $79.30 support, but traders should watch for a decisive break above $82.50â$82.60 or a pullback toward $76.60â$78.00 amid elevated volatility.
Sentiment & News
Key News Insights: ⢠FDA catalyst ⢠Growth expansion ⢠Trial risks GRAIL's Galleri FDA review is the key catalyst, with commercialization growth offset by NHS trial and financing risks.
AI Summary
GRAL is a catalyst-driven regulatory and reimbursement option on Galleri, not a proven diagnostics growth story: investors should watch the September 23 FDA panel closely, as a favorable outcome could unlock payer momentum while a skeptical review would expose negative margins, heavy cash burn, and a valuation already pricing in success.
Description
GRAIL, Inc. is a biotechnology firm based in Menlo Park, California, established in 2015. The company develops blood-based tests intended to detect cancer at early stages in asymptomatic individuals and to support faster diagnostic resolution when cancer is suspected, as well as tests for minimal residual disease and other post-diagnostic uses. GRAIL previously operated as a subsidiary of Illumina, Inc.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 26 | Dec 3 | GRAL | GRAIL, Inc. | Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside. | Closed | -8.1% |